Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Boosted by Natixis Advisors LLC

Natixis Advisors LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 290.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,562 shares of the biopharmaceutical company's stock after purchasing an additional 39,086 shares during the period. Natixis Advisors LLC owned about 0.06% of Ultragenyx Pharmaceutical worth $2,920,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $33,000. UMB Bank n.a. grew its stake in Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 352 shares during the period. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $56,000. Capital Performance Advisors LLP purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $107,000. Finally, KBC Group NV boosted its holdings in shares of Ultragenyx Pharmaceutical by 24.5% during the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock worth $143,000 after purchasing an additional 506 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 20,000 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This represents a 0.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,556 shares of company stock worth $1,515,967. 5.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

RARE has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Wedbush raised their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a "neutral" rating in a research report on Friday, August 2nd. The Goldman Sachs Group upped their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating on the stock in a report on Monday, August 5th. Finally, Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $87.46.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded down $0.12 during midday trading on Monday, reaching $47.12. 609,313 shares of the company's stock were exchanged, compared to its average volume of 784,822. The stock has a market capitalization of $4.35 billion, a PE ratio of -7.30 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 52-week low of $37.02 and a 52-week high of $60.37. The business's fifty day moving average price is $53.14 and its two-hundred day moving average price is $48.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm's revenue for the quarter was up 42.3% compared to the same quarter last year. During the same period last year, the business earned ($2.23) EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.